Inhaled Nitric Oxide (iNO) for PPHN: NICU Protocol, Dosing & Weaning Guide

Persistent Pulmonary Hypertension of the Newborn: Understanding PPHN

Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition characterized by failure of the normal postnatal transition from high to low pulmonary vascular resistance, resulting in right-to-left shunting through the foramen ovale and ductus arteriosus, and severe hypoxemia refractory to supplemental oxygen. PPHN complicates approximately 2 per 1000 live births and carries a mortality rate of 10-20% even with optimal management. Inhaled nitric oxide (iNO) is the only FDA-approved selective pulmonary vasodilator for term and near-term neonates with PPHN, and its use in Indian Level III NICUs has significantly improved survival outcomes.

Pathophysiology and Indications for iNO

PPHN may occur as a primary condition (idiopathic) or secondary to meconium aspiration syndrome (MAS), respiratory distress syndrome (RDS), congenital diaphragmatic hernia (CDH), sepsis/pneumonia, or pulmonary hypoplasia. Nitric oxide, a potent endogenous vasodilator, acts by stimulating soluble guanylate cyclase in pulmonary vascular smooth muscle, increasing cyclic GMP, and producing smooth muscle relaxation. When delivered via inhalation, iNO selectively dilates ventilated lung segments, reducing pulmonary vascular resistance without systemic hypotension.

Criteria for Initiating iNO Therapy

• Gestational age 34 weeks or greater (standard indication)
• Oxygenation index (OI) greater than 25 on two consecutive blood gases, where OI = (MAP x FiO2 x 100) / PaO2
• Echocardiographic evidence of pulmonary hypertension (elevated RV pressure, TR jet, right-to-left or bidirectional shunting at PDA or PFO)
• Exclusion of cyanotic congenital heart disease (critical pre-iNO echocardiography is mandatory)
• Failed response to optimal conventional ventilation, lung recruitment, and FiO2 of 1.0

iNO Dosing Protocol

Phase	Dose (ppm)	Duration	Assessment
Initiation	20 ppm	Start immediately	Check SpO2 and ABG at 30 and 60 minutes
Non-response trial	40 ppm (brief trial)	30-60 minutes maximum	If no improvement at 20 ppm; return to 20 if no benefit at 40
Maintenance	20 ppm (reduce to 5 ppm when stable)	Until weaning criteria met	Continuous SpO2, ABG every 4-6 hours
Weaning (phase 1)	Decrease by 5 ppm every 2-4 hours	From 20 to 5 ppm	Monitor for SpO2 drop of more than 5%
Weaning (phase 2)	Decrease by 1 ppm every 2-4 hours	From 5 to 1 ppm	If drop occurs, return to previous dose
Discontinuation	Stop from 1 ppm	Trial off for 30 min	If stable, discontinue; if desaturation, resume at 1-5 ppm

Critical Warning: Never abruptly discontinue iNO from doses above 5 ppm. Rebound pulmonary hypertension can cause acute cardiovascular collapse and death. Always wean gradually with continuous monitoring.

Delivery System Setup and Safety

iNO is delivered through the ventilator circuit using a specialized delivery device (such as INOmax DSIR or equivalent). The setup requires:

• iNO cylinder with regulator and flow controller integrated into the inspiratory limb of the ventilator circuit
• In-line NO analyzer (continuous monitoring of delivered NO concentration)
• In-line NO2 analyzer (must remain below 1 ppm to avoid pulmonary toxicity)
• Backup NO cylinder and delivery system immediately available
• Manual ventilation bag with NO delivery capability for transport or circuit disconnection

Ventilator Strategy During iNO Therapy

Optimal lung recruitment is essential for iNO efficacy. The drug can only reach pulmonary vasculature in ventilated alveoli. Key ventilator strategies include:

• Ensure adequate mean airway pressure (MAP) for lung recruitment; surfactant administration if indicated
• Avoid hyperventilation; target PaCO2 of 40-50 mmHg (permissive hypercapnia may be beneficial)
• Consider high-frequency oscillatory ventilation (HFOV) if conventional ventilation fails to achieve adequate lung expansion
• Maintain pH above 7.25 to optimize iNO response (acidosis reduces NO efficacy)

Monitoring Protocol During iNO Therapy

Parameter	Frequency	Target
SpO2 (pre- and post-ductal)	Continuous	Above 90-95%
Arterial blood gas	Every 4-6 hours (more frequently during initiation)	PaO2 60-80 mmHg, pH above 7.25
Methemoglobin level	At 4 hours, then every 12-24 hours	Below 5%
NO2 level in circuit	Continuous (in-line analyzer)	Below 1 ppm
Oxygenation index	With each ABG	Trending downward; target below 15
Echocardiography	At initiation, 24 hours, before weaning	Decreasing PA pressures, resolving shunts
Platelet count	Daily	Above 100,000/mcL

Response Assessment and Non-Responders

A positive response to iNO is defined as an improvement in PaO2 of at least 20 mmHg or SpO2 increase of more than 5% within 30-60 minutes of initiation. Approximately 60-70% of neonates with PPHN respond to iNO. For non-responders, the following steps should be considered:

1. Verify adequate lung recruitment and optimize ventilator settings
2. Correct acidosis, hypothermia, and metabolic derangements
3. Rule out structural congenital heart disease with detailed echocardiography
4. Consider trial dose increase to 40 ppm briefly
5. Add sildenafil (0.5-1 mg/kg PO/NG every 6-8 hours) as adjunctive pulmonary vasodilator
6. Consider milrinone infusion (0.33-0.99 mcg/kg/min) for combined inotropy and vasodilation
7. Refer for ECMO evaluation if OI remains above 40 despite maximal medical therapy (in centers with ECMO capability)

Adjunctive Therapies to iNO

Sildenafil

Sildenafil, a phosphodiesterase-5 inhibitor, augments the NO-cGMP pathway and is increasingly used as adjunctive therapy or for iNO weaning support. Dose: 0.5-1 mg/kg PO/NG every 6-8 hours. It is also a reasonable alternative in Indian Level II NICUs where iNO may not be available. NNF India recognizes sildenafil as a practical alternative for resource-limited settings.

Milrinone

Milrinone (phosphodiesterase-3 inhibitor) provides both pulmonary vasodilation and inotropic support. Loading dose 50 mcg/kg over 30-60 minutes (often omitted due to hypotension risk), followed by infusion at 0.33-0.99 mcg/kg/min. It is particularly useful when PPHN is associated with myocardial dysfunction.

Special Considerations for Indian NICUs

The availability and cost of iNO remain significant barriers in many Indian NICUs. Practical considerations include:

• Cost: iNO therapy costs approximately INR 5,000-15,000 per day depending on the supplier and delivery system, making it a significant financial consideration for families
• Availability: iNO is primarily available in Level III NICUs in metropolitan cities; smaller centers may need to rely on sildenafil as a substitute
• Transport: Neonates requiring iNO who are born in Level II centers need urgent transfer to Level III facilities with iNO capability; HEAMAC neonatal care resources can assist with identifying equipped centers and facilitating transport planning
• Training: All NICU staff involved in iNO administration must be trained in delivery system setup, monitoring protocols, and emergency management of device malfunction

Congenital Diaphragmatic Hernia and iNO

The role of iNO in CDH-associated PPHN is more nuanced. While iNO may provide temporary improvement, its efficacy is limited by pulmonary hypoplasia and abnormal pulmonary vasculature. The CDH EURO consortium and NNF India recommend using iNO in CDH only as a bridge to stabilization or ECMO, rather than definitive therapy. The underlying lung hypoplasia cannot be resolved by vasodilation alone.

Methemoglobinemia Management

iNO-induced methemoglobinemia occurs when nitric oxide oxidizes hemoglobin to methemoglobin, which cannot carry oxygen. Management protocol:

• Maintain methemoglobin level below 5% (check at 4 hours post-initiation, then every 12-24 hours)
• If level exceeds 5%, reduce iNO dose to the minimum effective level
• If level exceeds 7%, consider temporary discontinuation with close monitoring
• Methylene blue (1-2 mg/kg IV over 5 minutes) is the antidote for severe methemoglobinemia above 20% with clinical symptoms, but is rarely needed at standard iNO doses

Conclusion

Inhaled nitric oxide is a transformative therapy for neonates with PPHN, providing selective pulmonary vasodilation that has reduced the need for ECMO and improved survival globally. In India, expanding access to iNO in Level III NICUs while optimizing the use of sildenafil as an alternative in smaller centers represents the most practical approach to improving PPHN outcomes nationwide. Strict adherence to initiation criteria, monitoring protocols, and gradual weaning strategies is essential for safe and effective iNO therapy in every clinical setting.